. Author manuscript; available in PMC: 2011 Oct 9.

Published in final edited form as: Gastroenterology. 2009 Jun 12;137(3):856–864.e1. doi: 10.1053/j.gastro.2009.06.006

Table 4.

Overall and transplant-free survival according to etiology. Percentage, n and 95% CI.

	Overall Survival		Transplant-free survival

Etiology	Placebo	NAC	Placebo	NAC

DILI	65%, n=26	79%, n=19	27%, n=26	58%, n=19

N=45	45% – 86%	58% – 100%	8% – 46%	33% – 83%

AIH	67%, n=15	64%, n=11	27%, n=15	9%, n=11
N=26	34% – 94%	31% – 97%	1% – 52%	0% – 31%

HBV	50%, n=12	76%, n=25	17%, n=12	40%, n=25
N=37	18% – 83%	57% – 95%	0% – 42%	19% – 61%

Indeterminate	69%, n=26	60%, n=15	23%, n=26	40%, n=15
N=41	50% – 89%	32% – 88%	5% – 41%	12% – 68%

DILI – Drug induced liver injury; AIH – autoimmune hepatitis; HBV – hepatitis B virus. Patients with DILI or HBV appeared to have improved overall and transplant-free survival when compared to those with AIH or indeterminate ALF.